Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pyrintegrin 是一种 β1 整合素激动剂,也是 2,4-二取代的嘧啶,可促进胚胎干细胞存活。它可用作足细胞保护剂,能增强细胞-细胞外基质 (ECM) 粘附介导的整联蛋白信号传导,具有强大的成脂作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 625 | 现货 | ||
2 mg | ¥ 912 | 现货 | ||
5 mg | ¥ 1,470 | 现货 | ||
10 mg | ¥ 2,180 | 现货 | ||
25 mg | ¥ 3,990 | 现货 | ||
50 mg | ¥ 5,680 | 现货 | ||
100 mg | ¥ 7,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,620 | 现货 |
产品描述 | Pyrintegrin is an β1-integrin agonist that promotes embryonic stem cells' survival. Pyrintegrin can be used as a podocyte-protective agent. Pyrintegrin enhances cell-extracellular matrix adhesion-mediated integrin signaling. |
体外活性 | Pyrintegrin decreases Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation. Pyrintegrin treatment prevents damage-induced decreases in F-actin stress fibers, focal adhesions, and active β1-integrin levels in cultured cells. Pyrintegrin stimulates human adipose stem/progenitor cells (hASCs) to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells increasingly secreting adiponectin, leptin, glycerol, and total triglycerides. Pyrintegrin (0-10 μM; 1 hour; hASCs) treatment inhibits BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner (IC50 of 1.14 μM) [1][2]. |
体内活性 | Pyrintegrin induces postnatal adipose tissue formation in vivo of transplanted adipose stem/progenitor cells (ASCs) and recruited endogenous cells. Pyrintegrin decreases peak proteinuria caused by puromycin aminonucleoside-induced nephropathy. Pyrintegrin-treated human adipose stem/progenitor cells (ASCs) in 3D-bioprinted scaffolds, when transplanted in the dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ. Pyrintegrin-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation. Pyrintegrin (10 mg/kg; intraperitoneal injection; once; C57BL/6J mice) treatment protects mice from LPS-induced podocyte foot process effacement and proteinuria. LPS administration decreases the levels of active β1 integrin in the podocytes, which is prevented by cotreatment with Pyrintegrin [1][2]. |
分子量 | 451.54 |
分子式 | C23H25N5O3S |
CAS No. | 1228445-38-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (553.66 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2146 mL | 11.0732 mL | 22.1464 mL | 55.3661 mL |
5 mM | 0.4429 mL | 2.2146 mL | 4.4293 mL | 11.0732 mL | |
10 mM | 0.2215 mL | 1.1073 mL | 2.2146 mL | 5.5366 mL | |
20 mM | 0.1107 mL | 0.5537 mL | 1.1073 mL | 2.7683 mL | |
50 mM | 0.0443 mL | 0.2215 mL | 0.4429 mL | 1.1073 mL | |
100 mM | 0.0221 mL | 0.1107 mL | 0.2215 mL | 0.5537 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pyrintegrin 1228445-38-2 Cytoskeletal Signaling Integrin nephropathy C/EBPα embryonic stem inhibit β1-integrin PPARγ Adipogenic cells Inhibitor podocyte-protective ECM proteinuria inhibitor